Panel, Conference Presentation
Psychedelics: Mind-Enhancing Methods to Well-Being
Milken InstituteTim Ferriss, Christian Angermayer, Robin Carhart-Harris, Matthew Johnson, Ayelet Waldman
- Psilocybin is predicted to remain in Schedule I until FDA approval for an indication, at which point it is expected to be reclassified to Schedule IV based on safety data and lack of addiction potential, whereas MDMA and psilocybin currently hold FDA breakthrough therapy designation.
- The market outlook projects significant growth driven by the 320 million people suffering from depression, a rising global prevalence, and a 20-year history of neglected innovation, with a specific expectation that the opioid crisis may increase receptivity to rescheduling.
- Clinical development plans include randomized trials to follow up on smoking cessation pilot results, with expectations that MDMA and psilocybin efficacy graphs for PTSD and smoking cessation will be similar.
- The field anticipates treating a broad range of psychiatric disorders, with depression and anxiety associated with life-threatening cancer currently seen as the most promising indications, followed by smoking cessation, alcoholism, and general depression outside of cancer.
- Therapeutic mechanisms are described as a hybrid model where the breakdown of the default mode network allows for the revision of pathological beliefs and cultivation of healthy habits, with the quality of the psychedelic experience predicting reliable therapeutic outcomes.
- Safety profiles are characterized by a high physiological safety margin with no known lethal overdose or organ damage for psilocybin, LSD, or DMT, though risks include modest increases in blood pressure, headaches, falls from heights at high doses, and cardiac risks for specific MDMA patients.
- Adverse psychiatric reactions are expected in 1% to 2% of individuals with active psychotic disorders or strong predispositions, while hallucinogen persisting perceptual disorder is considered extremely rare and linked to recreational poly-drug use.
- Long-term sustainability of effects is predicted to be higher for psilocybin compared to ketamine's one-to-three-week antidepressant window, with claims that a single MDMA experience could sustain relationship improvements for up to two years.
- Regulatory and market shifts are projected to occur over the next decade, potentially involving state-level legalization similar to marijuana, federal funding secured through private philanthropy over the next three to five years, and a medicalized model driven by corporate and investment pressure.
- Societal trends are expected to exacerbate mental health issues over the next 20 years due to the dissolution of communities and families, necessitating a shift from current numbness-inducing treatments to holistic medical approaches.